Srugo I, Israele V, Wittek A E, Courville T, Vimal V M, Brunell P A
Division of Infectious Diseases, Ahmanson Pediatric Center, Cedars-Sinai Medical Center, UCLA, School of Medicine 90048.
Am J Dis Child. 1993 Jul;147(7):742-5. doi: 10.1001/archpedi.1993.02160310044016.
To study the clinical course of varicella-zoster infection in children infected with human immunodeficiency virus type I.
A clinical and laboratory study of human immunodeficiency virus-infected children was undertaken at Cedars-Sinai Medical Center, Los Angeles.
Twenty-seven human immunodeficiency virus-infected children aged 1 to 13 years who were treated between 1987 and 1992. Twenty-one children had acquired the infection through blood transfusion, 18 during the neonatal period and three during their early years of life. Six infants had acquired the infection perinatally.
Seventeen children have developed varicella, of whom 10 had an uncomplicated course and seven suffered from chronic, recurrent, or persistent varicella. Uncomplicated or recurrent varicella was a relatively benign illness that did not require antiviral therapy except in one child. In contrast, patients with persistent varicella required antiviral therapy as they were sicker and had a prolonged course. One had pneumonia, and another patient developed hyperkeratotic lesions that were refractory to therapy. They had lower CD4 counts (P < .01) and had a more advanced stage of the human immunodeficiency virus disease than the other children. Three patients who were receiving regular intravenous immunoglobulin developed their initial attack of varicella despite the presence of the varicella-zoster antibody. Four patients, three of whom had uncomplicated varicella, developed zoster involving one or two dermatomes. One patient developed zoster while receiving acyclovir therapy.
Children infected with human immunodeficiency virus type 1 may suffer unusual manifestations of varicella-zoster infection. The incidence of zoster in these children is higher than in the general population and is close to that in patients with leukemia. The effectiveness of antiviral therapy in these patients was difficult to evaluate.
研究感染I型人类免疫缺陷病毒的儿童水痘-带状疱疹感染的临床病程。
在洛杉矶锡达斯-西奈医疗中心对感染人类免疫缺陷病毒的儿童进行了一项临床和实验室研究。
1987年至1992年间接受治疗的27名1至13岁感染人类免疫缺陷病毒的儿童。21名儿童通过输血感染,18名在新生儿期感染,3名在幼年感染。6名婴儿在围产期感染。
17名儿童发生了水痘,其中10名病程无并发症,7名患有慢性、复发性或持续性水痘。无并发症或复发性水痘相对为良性疾病,除1名儿童外无需抗病毒治疗。相比之下,持续性水痘患者病情较重且病程延长,需要抗病毒治疗。1名患者患肺炎,另1名患者出现对治疗难治的角化过度病变。他们的CD4计数较低(P<0.01),且人类免疫缺陷病毒疾病阶段比其他儿童更严重。3名定期接受静脉注射免疫球蛋白的患者尽管存在水痘-带状疱疹抗体仍初次发作水痘。4名患者发生带状疱疹,其中3名无并发症水痘患者,累及1或2个皮节。1名患者在接受阿昔洛韦治疗时发生带状疱疹。
感染I型人类免疫缺陷病毒的儿童可能出现水痘-带状疱疹感染的异常表现。这些儿童带状疱疹的发病率高于普通人群,接近白血病患者。这些患者抗病毒治疗的效果难以评估。